A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

June 27, 2007

Primary Completion Date

May 25, 2011

Study Completion Date

May 25, 2011

Conditions
Mantle Cell Lymphoma
Interventions
DRUG

rituximab [MabThera/Rituxan]

375mg/m2 iv every 3 weeks

DRUG

First line chemotherapy

As prescribed

Trial Locations (7)

1122

National Institute of Oncology, A Dept of Internal Medicine, Budapest

3529

Miskolci Semmelweis Korhaz; Ii Belgyogyaszat, Miskolc

4032

University of Debrecen Medical and Health Science Center, Institute of Internal Medicine, Hematology, Debrecen

6720

University of Szeged, II Dept of Internal Medicine, Szeged

7400

Kaposi Mor Teaching Hospital, Dept of Internal Medicine/Hematology, Kaposvár

8901

Zala Megyei Korhaz; Ii. Belgyogyaszat, Zalaegerszeg

9024

Petz Aladar Megyei Korhaz; Hematologia, Győr

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00472420 - A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma. | Biotech Hunter | Biotech Hunter